Korro Bio, Inc. (KRRO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $9.78 (-17.12%), Market cap $0.14B, 52-week low–high $5.28 ~ $51.36.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic d
Financial statements, price targets, institutional (13F) holdings and related news for Korro Bio, Inc. are updated in real time on BlackAll Trade.
Korro Bio, Inc. trades at $9.78 (-17.12%). Real-time quotes and charts are available on BlackAll Trade.
Korro Bio, Inc. has a market cap of about $0.14B.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent disea